{
"indication": {
"drug": "Cetuximab (Erbitux)",
"disease": "Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma",
"line": "1L with platinum/5-FU, monotherapy after platinum failure",
"setting": "R/M HNSCC (oral, pharyngeal, laryngeal)",
"last_updated": "2025-10-03",
"updated_by": "GPT-5 Thinking"
},
"direct_competitors": [
{
"drug": "Pembrolizumab + platinum/5-FU",
"company": "Merck (MSD)",
"moa": "PD-1 monoclonal antibody (with chemotherapy)",
"status": "FDA approved (1L R/M HNSCC)",
"threat_level": "HIGH",
"rationale": "Established 1L standard replacing cetuximab-based EXTREME in PD-L1–positive disease and broadly used regardless of HPV status.",
"keywords": ["KEYNOTE-048", "pembrolizumab", "pembro", "keytruda", "PD-L1 CPS", "first-line", "EXTREME"]
},
{
"drug": "Pembrolizumab (monotherapy, CPS ≥1)",
"company": "Merck (MSD)",
"moa": "PD-1 monoclonal antibody",
"status": "FDA approved (1L for CPS ≥1; later-line regardless of CPS)",
"threat_level": "HIGH",
"rationale": "Preferred 1L option in CPS ≥1 and CPS ≥20, directly displacing cetuximab-containing regimens.",
"keywords": ["KEYNOTE-048", "pembrolizumab", "pembro", "keytruda", "CPS 1-19", "CPS ≥20", "first-line monotherapy"]
},
{
"drug": "Nivolumab",
"company": "Bristol Myers Squibb",
"moa": "PD-1 monoclonal antibody",
"status": "FDA approved (post-platinum)",
"threat_level": "MEDIUM",
"rationale": "Standard after platinum failure, reducing later-line cetuximab monotherapy use.",
"keywords": ["nivolumab", "opdivo", "CheckMate 141", "CheckMate-141", "post-platinum", "second-line"]
},
{
"drug": "Taxane chemotherapy (docetaxel/paclitaxel)",
"company": "Generic",
"moa": "Microtubule inhibitor (cytotoxic)",
"status": "Guideline-recommended option (post-IO/chemo)",
"threat_level": "LOW",
"rationale": "Competes for later-line use where cetuximab monotherapy was historically used.",
"keywords": ["docetaxel", "paclitaxel", "investigator's choice", "salvage therapy"]
}
],
"emerging_threats": [
{
"drug": "Tipifarnib",
"company": "Kura Oncology",
"moa": "Farnesyl transferase inhibitor",
"phase": "Phase 2 (pivotal, AIM-HN/SEQ-HN)",
"biomarker": "HRAS-mutant HNSCC (~4–8%)",
"threat_level": "MEDIUM",
"keywords": ["tipifarnib", "HRAS mutation", "AIM-HN", "SEQ-HN", "head and neck"]
},
{
"drug": "AFM24 ± anti–PD-(L)1",
"company": "Affimed (and collaborators)",
"moa": "EGFR×CD16A bispecific innate cell engager (NK/macrophage)",
"phase": "Phase 1/2",
"biomarker": "EGFR-expressing tumors (includes HNSCC cohorts)",
"threat_level": "LOW",
"keywords": ["AFM24", "innate cell engager", "EGFR CD16A", "HNSCC cohort"]
},
{
"drug": "REGN7075 ± cemiplimab",
"company": "Regeneron",
"moa": "EGFR×CD28 costimulatory bispecific (± PD-1)",
"phase": "Phase 1/2",
"biomarker": "EGFR-expressing tumors (includes HNSCC cohorts)",
"threat_level": "LOW",
"keywords": ["REGN7075", "EGFRxCD28", "cemiplimab", "HNSCC expansion"]
},
{
"drug": "Patritumab deruxtecan (HER3-DXd)",
"company": "Daiichi Sankyo / Merck",
"moa": "HER3-directed antibody–drug conjugate",
"phase": "Phase 2 (pan-tumor; HNSCC cohorts planned/ongoing)",
"biomarker": "HER3 expression (exploratory)",
"threat_level": "LOW",
"keywords": ["HER3-DXd", "patritumab deruxtecan", "head and neck cohort", "ADC"]
},
{
"drug": "Pembrolizumab + lenvatinib",
"company": "Merck (MSD) / Eisai",
"moa": "PD-1 inhibitor + VEGFR/FGFR TKI",
"phase": "Phase 3 (LEAP-010; negative OS)",
"biomarker": "Unselected (PD-L1 stratified analyses)",
"threat_level": "LOW",
"keywords": ["LEAP-010", "lenvatinib", "negative OS", "first-line HNSCC"]
}
],
"key_biomarkers": [
{
"biomarker": "PD-L1 Combined Positive Score (CPS)",
"clinical_utility": "Selects 1L pembrolizumab monotherapy (CPS ≥1) and enriches benefit for pembrolizumab ± chemo; informs IO vs cetuximab regimens.",
"prevalence": "CPS ≥1 in ~70–85% of R/M HNSCC; CPS ≥20 in ~30–35%",
"keywords": ["PD-L1", "CPS", "22C3", "KEYNOTE-048"]
},
{
"biomarker": "HPV/p16 status (primarily oropharyngeal)",
"clinical_utility": "Prognostic; HPV+ disease has better outcomes and may influence treatment intensity and expectations.",
"prevalence": "HPV+ in ~60–70% of oropharyngeal; lower in oral cavity/larynx",
"keywords": ["HPV", "p16", "oropharyngeal", "prognosis"]
},
{
"biomarker": "HRAS mutation",
"clinical_utility": "Identifies candidates for farnesyl transferase inhibition (e.g., tipifarnib) in R/M setting.",
"prevalence": "~4–8% overall; enriched in oral cavity primaries",
"keywords": ["HRAS", "farnesyl transferase", "tipifarnib"]
},
{
"biomarker": "Tumor Mutational Burden (TMB-high)",
"clinical_utility": "Tissue-agnostic indication for pembrolizumab (TMB ≥10 mut/Mb) may support IO use when PD-L1 is low/negative.",
"prevalence": "Subset (~10–20% depending on cutoff/assay)",
"keywords": ["TMB", "mut/Mb", "tissue-agnostic", "pembrolizumab"]
},
{
"biomarker": "EGFR overexpression/amplification",
"clinical_utility": "Biologic rationale for EGFR targeting (cetuximab, emerging EGFR engagers/ADCs); not a robust predictive marker.",
"prevalence": "Common in HNSCC (majority overexpress EGFR)",
"keywords": ["EGFR", "overexpression", "amplification", "IHC", "FISH"]
}
],
"hpv_stratification": [
{
"hpv_status": "HPV-positive",
"prognosis": "Better",
"treatment_differences": "Pembrolizumab ± chemo remains preferred in 1L; de-escalation strategies are investigational. Cetuximab-based regimens used less often in 1L.",
"keywords": ["HPV+", "p16+", "oropharyngeal", "better prognosis", "IO benefit"]
},
{
"hpv_status": "HPV-negative",
"prognosis": "Worse",
"treatment_differences": "Higher-risk biology; pembrolizumab + chemotherapy commonly favored in CPS-low/negative disease; cetuximab usage largely limited to select cases.",
"keywords": ["HPV−", "p16−", "aggressive", "chemoimmunotherapy"]
}
],
"paradigm_shifts": [
{
"old": "EXTREME regimen (cetuximab + platinum/5-FU) as default 1L",
"new": "Pembrolizumab ± platinum/5-FU as preferred 1L based on PD-L1 CPS",
"impact": "Material loss of 1L share for cetuximab-containing regimens; repositioned mainly to non-IO niches or combinations.",
"year": "2019-2025"
},
{
"old": "Cytotoxic chemotherapy as standard after platinum failure",
"new": "PD-1 inhibitors (nivolumab, pembrolizumab) in post-platinum disease",
"impact": "Reduces later-line cetuximab monotherapy utilization.",
"year": "2016-2022"
},
{
"old": "Minimal biomarker use beyond site/stage",
"new": "PD-L1 CPS and HPV/p16 status routinely considered in 1L decisions",
"impact": "Shifts prescribing from cetuximab toward PD-1–based regimens in eligible patients.",
"year": "2019-2024"
}
],
"exclusions": {
"settings": ["Adjuvant therapy", "Neoadjuvant therapy", "Definitive chemoradiation for locally advanced disease"],
"rationale": "Non-R/M settings not competitive with recurrent/metastatic indication"
}
}